Skip to main content

Table 2 Uncorrected and PCR-corrected treatment outcomes at days 28 and 42 for artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ), Mali 2015–2016

From: Therapeutic efficacy of artemether–lumefantrine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, 20152016

  AL 95% CI ASAQ 95% CI p-value
   Lower Upper   Lower Upper  
Uncorrected treatment outcomes—day 28
 Number reaching an endpoint 217     217     
 Early treatment failure 14 6.5% 3.2% 9.7% 3 1.4% 0.0% 2.9% 0.006
 Late clinical failure 10 4.6%    5 2.3%    
 Late parasitological failure 12 5.5%    7 3.2%    
 Adequate clinical and parasitological response at day 28 181 83.4% 78.5% 88.4% 202 93.1% 89.7% 96.5% 0.002
Uncorrected treatment outcomes—day 42
 Number reaching an endpoint 212     214     
 Early treatment failure 14 6.6% 3.3% 9.9% 3 1.4% 0.0% 3.0% 0.006
 Late clinical failure 15 7.1%    9 4.2%    
 Late parasitological failure 29 13.7%    22 10.3%    
Adequate clinical and parasitological response at day 42 154 72.6% 66.6% 78.6% 180 84.1% 78.3% 89.9% 0.004
PCR corrected treatment outcomes—day 28
 Number reaching an endpoint 217     217     
 Early treatment failure 14 6.5% 3.2% 9.7% 3 1.4% 0.0% 2.9% 0.006
 Recrudescent cases 4 1.8%    3 1.4%    
 Total new infections 18 8.3%    9     
 Day 7–14 1     2     
 Day 15–21 10     1     
 Day 22–28 7     6     
 Adequate clinical and parasitological response at day 28 181 91.0% 86.0% 95.9% 202 97.1% 93.6% 100.0% 0.008
PCR corrected treatment outcomes—day 42
 Number reaching an endpoint 212     214     
 Early treatment failure 14 6.6% 3.3% 9.9% 3 1.4% 0.0% 3.0% 0.006
 Recrudescent cases 5 2.4%    4 1.9%    
 Total new infections 39 18.4%    27 12.6%    
 Day 7–14 1     2     
 Day 15–21 10     1     
 Day 22–28 7     6     
 Day 29–35 16     12     
 Day 36–42 5     6     
 Adequate clinical and parasitological response at day 42 154 89.0% 83.0% 95.0% 180 96.3% 91.0% 100.0% 0.008
  1. p < 0.05